AXGN:NASDAQ
AxoGen, Inc Common Stock
$55.38
arrow_downward
-0.97%(-0.55) 1D
Nov 16, 9:55:33 AM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
$55.56
High
$56.35
Low
$55.08
Mkt. cap
3.31B
Avg. vol.
1.92M
Volume
28.18K
52-wk high
$59.72
52-wk low
$23.00
EPS
-$0.68
Beta
1.21
Shares outstanding
59.73M
No. of employees
622
Open
$55.56
High
$56.35
Low
$55.08
Mkt. cap
3.31B
Avg. vol.
1.92M
Volume
28.18K
52-wk high
$59.72
52-wk low
$23.00
EPS
-$0.68
Beta
1.21
Shares outstanding
59.73M
No. of employees
622
News stories
From web sources and news partners
upi
·
19 minutes ago
KB Kookmin Bank debuts S&P 500-linked dollar deposit product
CNBC
·
35 minutes ago
Morgan Stanley is out with its 2027 outlook for equities. Here’s what the bank expects
FXEmpire
·
1 hour ago
Why The S&P 500 Could Fall 63% – And Still Only Be Fairly Valued
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Florida, United States
SectorHealth Care
IndustryMedical device
Websiteaxogeninc.com